Clinical trials with targeted therapy for R/R ALCL
| Protocol . | Drug . | Time frame . | No. of patients . | Age range . | ORR . | Location . | Reference . |
|---|---|---|---|---|---|---|---|
| ADVL0912 | Crizotinib | 2009-2015 | 26 | 1 to <22 y | 90% (280 mg/m2) | North America | 29 |
| C25002 | Brentuximab | 2012-2016 | 17 | 2 to <17 y | 53% | International | 31 |
| UMIN000016991 | Alectinib | 2015-2017 | 10 | ≥6 y | 80% | Japan | 51 |
| CLDK378X2103 | Ceritinib | 2013-2017 | 12 | 1 to <18 y | 75% | International | 52 |
| AcSé-crizotinib | Crizotinib | 2014-2018 | 24 | ≥1 y | 67% | France | 53 |
| NCT02419287 and EudraCT 2010-022978-14 | Crizotinib | 2010-2019 | 27∗ | ≥18 y | 80% | Italy | 54 |
| CRISP/ITCC053 | Vinblastine/crizotinib | 2016-2021 | 13 | 1 to <18 y | 92% | Europe | 55 |
| BrigaPED/ITCC098 | Brigatinib | 2022-2024 | 9 | 1 to <18 y | 100% | France/The Netherlands | 56 |
| CRU3 | Lorlatinib | 2017 to ongoing | — | ≥18 y | — | Italy | — |
| EICNHL NIVO-ALCL | Nivolumab | 2019 to ongoing | — | >6 mo | — | Europe | — |
| DETERMINE Trial | Alectinib | 2023 to ongoing | — | Any† | — | United Kingdom | — |
| NCT07001384 | Alectinib/duvelisib | 2025 to ongoing | — | ≥18 y | — | United States | — |
| Protocol . | Drug . | Time frame . | No. of patients . | Age range . | ORR . | Location . | Reference . |
|---|---|---|---|---|---|---|---|
| ADVL0912 | Crizotinib | 2009-2015 | 26 | 1 to <22 y | 90% (280 mg/m2) | North America | 29 |
| C25002 | Brentuximab | 2012-2016 | 17 | 2 to <17 y | 53% | International | 31 |
| UMIN000016991 | Alectinib | 2015-2017 | 10 | ≥6 y | 80% | Japan | 51 |
| CLDK378X2103 | Ceritinib | 2013-2017 | 12 | 1 to <18 y | 75% | International | 52 |
| AcSé-crizotinib | Crizotinib | 2014-2018 | 24 | ≥1 y | 67% | France | 53 |
| NCT02419287 and EudraCT 2010-022978-14 | Crizotinib | 2010-2019 | 27∗ | ≥18 y | 80% | Italy | 54 |
| CRISP/ITCC053 | Vinblastine/crizotinib | 2016-2021 | 13 | 1 to <18 y | 92% | Europe | 55 |
| BrigaPED/ITCC098 | Brigatinib | 2022-2024 | 9 | 1 to <18 y | 100% | France/The Netherlands | 56 |
| CRU3 | Lorlatinib | 2017 to ongoing | — | ≥18 y | — | Italy | — |
| EICNHL NIVO-ALCL | Nivolumab | 2019 to ongoing | — | >6 mo | — | Europe | — |
| DETERMINE Trial | Alectinib | 2023 to ongoing | — | Any† | — | United Kingdom | — |
| NCT07001384 | Alectinib/duvelisib | 2025 to ongoing | — | ≥18 y | — | United States | — |